<DOC>
	<DOCNO>NCT01932125</DOCNO>
	<brief_summary>This multicenter prospective observational study evaluate safety efficacy Avastin ( bevacizumab ) routine clinical practice patient advanced/metastatic epithelial ovarian cancer , fallopian tube cancer primary peritoneal cancer . Data collect eligible patient death , withdrawal consent , loss follow-up , study closure .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Patients With Advanced/Metastatic Epithelial Ovarian Cancer , Fallopian Tube Cancer Primary Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Prescribed receive Avastin already ongoing treatment Avastin advanced/metastatic ovarian cancer , fallopian tube cancer primary peritoneal cancer ( FIGO Stage IIIb , IIIc IV ) accord routine clinical practice Not eligible treatment Avastin accord local prescribing information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>